KR20100065171A - 티아디아지논 유도체 - Google Patents

티아디아지논 유도체 Download PDF

Info

Publication number
KR20100065171A
KR20100065171A KR1020107006823A KR20107006823A KR20100065171A KR 20100065171 A KR20100065171 A KR 20100065171A KR 1020107006823 A KR1020107006823 A KR 1020107006823A KR 20107006823 A KR20107006823 A KR 20107006823A KR 20100065171 A KR20100065171 A KR 20100065171A
Authority
KR
South Korea
Prior art keywords
salts
solvates
nha
naa
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107006823A
Other languages
English (en)
Korean (ko)
Inventor
올리버 샤트
디에터 도르슈
프랑크 슈티버
안드레 블라우카트
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20100065171A publication Critical patent/KR20100065171A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107006823A 2007-08-30 2008-08-06 티아디아지논 유도체 Withdrawn KR20100065171A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007041115.6 2007-08-30
DE102007041115A DE102007041115A1 (de) 2007-08-30 2007-08-30 Thiadiazinonderivate

Publications (1)

Publication Number Publication Date
KR20100065171A true KR20100065171A (ko) 2010-06-15

Family

ID=39952448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107006823A Withdrawn KR20100065171A (ko) 2007-08-30 2008-08-06 티아디아지논 유도체

Country Status (16)

Country Link
US (1) US8211886B2 (enExample)
EP (1) EP2181111B1 (enExample)
JP (1) JP5524840B2 (enExample)
KR (1) KR20100065171A (enExample)
CN (1) CN101784544B (enExample)
AR (1) AR068130A1 (enExample)
AU (1) AU2008295193B2 (enExample)
BR (1) BRPI0816058A2 (enExample)
CA (1) CA2698062C (enExample)
DE (1) DE102007041115A1 (enExample)
EA (1) EA017393B1 (enExample)
ES (1) ES2426356T3 (enExample)
IL (1) IL204127A (enExample)
MX (1) MX2010002096A (enExample)
WO (1) WO2009030333A1 (enExample)
ZA (1) ZA201002218B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
KR100626605B1 (ko) 1997-11-19 2006-09-22 코와 가부시키가이샤 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CZ2004516A3 (cs) 2001-10-31 2004-08-18 Merckápatentágmbh Inhibitor fosfodiesterázy typu @Ź jeho kombinace s jinými drogami a jeho použití
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate

Also Published As

Publication number Publication date
US8211886B2 (en) 2012-07-03
ES2426356T3 (es) 2013-10-22
CN101784544A (zh) 2010-07-21
AU2008295193B2 (en) 2013-04-18
US20100311733A1 (en) 2010-12-09
EP2181111B1 (de) 2013-06-26
EP2181111A1 (de) 2010-05-05
DE102007041115A1 (de) 2009-03-05
JP2010536896A (ja) 2010-12-02
HK1146276A1 (en) 2011-05-20
CA2698062A1 (en) 2009-03-12
AU2008295193A1 (en) 2009-03-12
JP5524840B2 (ja) 2014-06-18
WO2009030333A1 (de) 2009-03-12
AR068130A1 (es) 2009-11-04
CN101784544B (zh) 2012-08-29
MX2010002096A (es) 2010-03-26
EA017393B1 (ru) 2012-12-28
IL204127A (en) 2013-08-29
BRPI0816058A2 (pt) 2015-03-31
ZA201002218B (en) 2010-12-29
EA201000364A1 (ru) 2010-08-30
CA2698062C (en) 2016-05-31

Similar Documents

Publication Publication Date Title
JP5426544B2 (ja) ピリミジニル−ピリダジノン誘導体
JP5443381B2 (ja) Ｍｅｔキナーゼ阻害剤としての２−ベンジルピリダジノン誘導体
JP5662143B2 (ja) 腫瘍の処置のためのＭｅｔキナーゼ阻害剤としての２−オキソ−３−ベンジルベンゾキサゾール−２−オン誘導体、および関連する化合物
CN102264727B (zh) 哒嗪酮衍生物
JP5576358B2 (ja) ピリダジノン誘導体
KR101661777B1 (ko) Ｍｅｔ 키나아제 저해제로서의 3-（3-피리미딘-2-일-벤질）-〔1,2,4〕트리아졸로〔4,3-ｂ〕피리다진 유도체
KR20110051243A (ko) 종양 치료용 비시클릭 트리아졸 유도체
CN102272125B (zh) 哒嗪酮衍生物
KR20080039992A (ko) 1-아실디히드로피라졸 유도체
KR20110102504A (ko) 벤조티아졸론 유도체
KR20110099742A (ko) 3-(3-피리미딘-2-일-벤질)-［1,2,4］트리아졸로［4,3-ｂ］피리미딘 유도체
KR20100065171A (ko) 티아디아지논 유도체
KR20110010821A (ko) 종양 치료를 위한 티로신 키나아제 조정제로서의 디히드로피라졸 유도체
KR20110098852A (ko) 3-(3-피리미딘-2-일-벤질)-［1,2,4］트리아졸로［4,3-ｂ］피리다진 유도체
KR20110099799A (ko) 피리다지논 유도체
HK1146276B (en) Thiadiazinone derivatives
HK1151291B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid